{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-056478","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2021-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.609780+00:00","generated_at":"2026-06-28T09:17:21.838352+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Prelude Therapeutics Q3 loss widens to $30.7M; CFO and CMO depart; cash $320.9M","bullets":["Q3 net loss $30.7M ($0.66/sh) vs $16.8M loss in Q3 2020; cash, equivalents and securities $320.9M.","CFO Brian Piper resigns effective Nov 19; Laurent Chardonnet appointed CFO from Nov 29.","CMO Dr. David Mauro mutually agreed to depart Nov 9; search for successor ongoing.","PRT2527 IND cleared; Phase 1 trial to start by year-end; PRT543/811 expansion data expected in 2022.","Retention bonus of $200k approved for EVP Deborah Morosini if employed through Nov 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-056478","json":"https://secwatch.observer/filing/0001564590-21-056478.json","markdown":"https://secwatch.observer/filing/0001564590-21-056478.md","text":"https://secwatch.observer/filing/0001564590-21-056478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000156459021056478/0001564590-21-056478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000156459021056478/prld-8k_20211105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:17:21.838352+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2be044cf11","claim":"Laurent Chardonnet was appointed as Chief Financial Officer at Prelude Therapeutics Inc.","evidence_excerpt":"On November 5, 2021, the Board of Directors of the Company (the “Board”) appointed Laurent Chardonnet as the Chief Financial Officer of the Company, including as the “principal financial officer” and “principal accounting officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective on or about November 29, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000156459021056478/0001564590-21-056478-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c044e5fac7","claim":"Brian Piper resigned as Chief Financial Officer at Prelude Therapeutics Inc.","evidence_excerpt":"On November 5, 2021, Brian Piper, the Chief Financial Officer of the Company, notified the Company that he will be resigning from the Company, effective November 19, 2021, to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000156459021056478/0001564590-21-056478-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}